Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma

Olivia BEAUDOUX1,2, Marine EHRET3, Emilie CRIQUET3, Joséphine FRANCESCHI3, Anne DURLACH1, Jean-Baptiste OUDART4–6, Laetitia VISSEAUX1 and Florent GRANGE2,3,7

1Department of Pathology, 2Department of Oncodermatology and 3Laboratory of Biochemistry, Pharmacology and Toxicology, Reims University Hospital, FR-51100 Reims, 4EA (“équipe d’accueil”) 7509: immune dysregulation and tissue remodelling in cancer, autoimmune and inflammatory diseases, 5Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, University of Reims Champagne-Ardenne, SFR CAP-Santé (FED 4231), 6CNRS UMR 7369, “Matrice Extracellulaire et Dynamique Cellulaire” - MEDYC, Reims, and 7Department of Dermatology, Valence Hospital, Valence, France. E-mail: obeaudoux@chu-reims.fr

Accepted Nov 30, 2020; Epub ahead of print Dec 7, 2020

Primary penile melanoma (PM) is a rare malignant mucosal tumour with poor prognosis. The mainstay of initial treatment is surgery, but excision with adequate margins often requires penile amputation, which may result in major impairment in the patient’s quality of life without improving survival (1). Unresectable and metastatic cases of PM are difficult to treat because of poor efficacy of new treatments, which have recently transformed the prognosis of advanced cutaneous melanomas (CMs). Checkpoint inhibitors have not been specifically evaluated in PMs, but the response rate of patients with metastatic mucosal melanoma (MM) treated with anti-CTLA-4 or anti-PD-1 antibodies remains low (2). The oncogenic drivers of PMs are widely unknown because of the rarity of this tumour. In MMs from other mucous sites, the main drivers commonly found in CMs (i.e. BRAF and NRAS) have low mutation rates (3). In contrast, KIT mutations are more frequent in MMs (13%) than in CMs (3). Responses to KIT inhibitors, such as imatinib, have been reported in KIT-mutated MMs (4). Although these responses were more often partial and of short duration, complete and long-term responses have also been reported (4, 5). To the best of our knowledge, no patient with KIT-mutant metastatic PM and response to KIT inhibitors has been reported to date.

CASE REPORT

A 69-year-old man consulted for a PM. He had a 10-year history of hyperpigmentation on the glans and adjacent foreskin, with nodular development over 8 months. Physical examination revealed a 4×3 cm pigmented macula of the glans and adjacent foreskin (Fig. 1a) with a 12×8 mm, thick, nodule at the balano-preputial junction, without lymphadenopathy. Histopathological examination of the nodule showed a malignant, BRAF wild-type melanoma. Whole-body 18F-Fluorodeoxyglucose positron emission computed tomography evaluation was otherwise negative. The patient declined radical, mutilating surgery and was therefore first treated with the anti-PD-1 antibody pembrolizumab. After 8 months, the penile nodule increased in size and palpable inguinal lymph nodes appeared, without detectable distant metastases. Bilateral radical lymph node dissection was positive for melanoma in 2 nodes on the right side and 1 node on the left side. After receiving 3 doses of the anti-CTLA-4 antibody ipilimumab, the patient developed a grade-2 colitis requiring systemic corticosteroids, and a solitary brain metastasis, which was treated with stereotactic radiotherapy. Pembrolizumab was then rechallenged, until lung and pleural metastases were visualized on F-FDG PET/CT and confirmed by histopathological examination 6 months later, along with growing penile metastatic nodules (Fig. 1b). Next-generation sequencing molecular analysis of 1 nodule identified double pathogenic KIT mutations, in exon 11 (c.1727T>C, L576P) and exon 18 (c.2540C>T, T847M). The patient was given imatinib, 400 mg twice per day, with good tolerance. The penile nodules disappeared rapidly and the brain MRI and whole-body F-FDG PET/CT, performed after 3 months of therapy, did not show any residual metastasis, while the CT scan still visualized a small pleural nodule, consistent with a complete metabolic, nearly morphologically complete, remission. After a progression-free period of 6 months, lung and pleural metastases recurred. The patient received 7 cycles of dacarbazine, leading to a partial response, followed by progression. The anti-PD-1 antibody nivolumab was then administered, once again with a partial response. The patient’s lactate dehydrogenase level was normal. The patient was alive in good general condition with only a minor residual disease 2 years after first distant (brain) metastases and 18 months after the initiation of imatinib for rapid progression.

DISCUSSION

To our knowledge, this is the first reported case of a KIT-mutated PM treated successfully with a KIT inhibitor. Also rare, the KIT L576P mutation is the most common oncogenic KIT variant in melanomas (5). The
KIT T847M mutation has been reported in one case of conjunctival melanoma (6) and is considered pathogenic (https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=165056644).

An exhaustive literature review (references available on request) identified one KIT mutation (Q575_P577del in exon 11) (7) among 21 cases of PMs tested for KIT. In these cases, no details of treatment or outcome were given. Most responses in KIT-mutated melanomas and other KIT-mutated tumours as gastrointestinal stromal tumours (GISTs) have been observed in patients with exon 11 variants (5). In contrast, patients with exon 18 KIT-mutated tumours generally had no response. The dramatic response observed in the current patient with both exon 11 and 18 mutations is therefore of interest.

Unexpected responses to chemotherapies or previously ineffective treatments have been reported after responses to various emerging therapies, suggesting that an initial response may modify the molecular profiles and sensitivity of tumour cells (8). We therefore hypothesize that the current patient benefitted from the KIT therapy beyond the initial response.

Although the frequency of KIT mutations in PMs remains unknown (1/21=4.8%, 95% confidence interval 0–14%) and seems lower than that of vulvo-vaginal melanoma (35%) and head and neck melanoma (25%) (3), our observation suggests that a molecular analysis including KIT should be performed before any decision is made to use aggressive surgical treatment or systemic therapy in patients with PM.

ACKNOWLEDGEMENTS

The patient has provided informed consent for publication, including medical photography.

The authors have no conflicts of interest to declare.

REFERENCES

1. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 2005; 173: 1958–1965.
2. Mignard C, Deschamps Huvier A, Gillibert A, Duval Modeste AB, Dutriaux C, Khammari A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J Oncol 2018; 2018: 1908065.
3. Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol 2020; 61: 139–148.
4. Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, et al. STAT3 mediates nilotinib response in KIT-altered melanoma: a phase II multicenter trial of the French skin cancer network. J Invest Dermatol 2018; 138: 58–67.
5. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman R-A, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327–2334.
6. Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19: 3143–3152.
7. Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res Off J Am Assoc Cancer Res 2011; 17: 3933–3942.
8. Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, Varey E, Quéreux G, et al. Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. Medicine (Baltimore) 2020; 99: e21329.